Natera Inc is a biotechnology company that focuses on providing innovative genetic testing services for various medical applications. The company specializes in non-invasive prenatal testing, environmental DNA analysis, and oncology, utilizing advanced genetic insights to aid in disease detection and management. By leveraging its proprietary technology and bioinformatics, Natera aims to improve patient outcomes and facilitate personalized medicine through comprehensive genomic solutions that empower healthcare providers and patients alike. Read More
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. 23, at 5:00 a.m. PT (8:00 a.m. ET) to discuss data in muscle-invasive bladder cancer that will be presented at the European Society for Medical Oncology (ESMO) Congress. This includes results from the randomized phase 3 IMvigor011 trial and from Checkmate 274.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 17–21 in Berlin, Germany. The slate includes six oral presentations, reinforcing Natera’s position as a leader in molecular residual disease (MRD) testing across multiple cancer types.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Clinical Oncology - Precision Oncology (JCO PO). The paper features results from a multi-institutional study evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker for patients with germ cell tumors (GCT), including testicular cancer.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.5% in the afternoon session after Wells Fargo & Company initiated coverage on the stock with a neutral "equal weight" rating and set a price target of $175.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 2.7% in the afternoon session after the company reached an $8.25 million settlement in a legal case. The case, titled 'Amanda Davis v. Natera Inc.,' was reported by the Daily Journal. While the financial impact of the settlement may not be substantial for a company of Natera's scale, news of legal disputes can create uncertainty among investors. The announcement may have raised concerns regarding the underlying issues of the lawsuit or the potential for future legal challenges, prompting a sell-off in the company's shares.
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood test.
Since September 2020, the S&P 500 has delivered a total return of 94.8%. But one standout stock has doubled the market - over the past five years, Natera has surged 186% to $176.64 per share. Its momentum hasn’t stopped as it’s also gained 33.2% in the last six months thanks to its solid quarterly results, beating the S&P by 17.2%.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 0.9% in the morning session after the company announced an unfavorable court ruling in its ongoing patent litigation with competitor NeoGenomics.
NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boosting investor sentiment.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc.
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 3% in the afternoon session after the company announced its Signatera molecular residual disease test was selected for a Phase III clinical trial for muscle-invasive bladder cancer.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in muscle-invasive bladder cancer (MIBC). The study is evaluating whether a shorter course of radiation can achieve outcomes comparable to the current standard of care. It prospectively incorporates Signatera, Natera’s personalized, tumor-informed molecular residual disease (MRD) test, as a pre-specified secondary endpoint.
